Forimtamig

An investigational T-cell–engaging bispecific antibody

Forimtamig is designed with a 2:1 structure to bivalently bind to GPRC5D, a G protein–coupled receptor highly expressed on malignant plasma cells, and monovalently bind to CD3 on T cells¹

CD=cluster of differentiation; GPRC5D=G protein-coupled receptor class C group 5 member D.